Format

Send to

Choose Destination
Sci Rep. 2016 May 31;6:26801. doi: 10.1038/srep26801.

Plasma β-amyloid in Alzheimer's disease and vascular disease.

Author information

1
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
2
Memory Clinic, Skåne University Hospital, Malmö Sweden.
3
Department of Neurology, Skåne University Hospital, Lund, Sweden.
4
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
5
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.
6
Department of Clinical Sciences Lund, Diagnostic radiology, Lund University, Lund, Sweden.
7
Imaging and Function, Skåne University Health Care, Lund, Sweden.
8
Quanterix Corporation, 113 Hartwell Avenue, Lexington, MA, USA.
9
Diagnostics and Life Sciences, GE Global Research, Niskayuna, NY, USA.
10
Janssen R&D, Titusville, NJ, USA.

Abstract

Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.

PMID:
27241045
PMCID:
PMC4886210
DOI:
10.1038/srep26801
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center